These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

182 related articles for article (PubMed ID: 17021257)

  • 1. Therapeutic potential of phosphatidylinositol 3-kinase inhibitors in inflammatory respiratory disease.
    Ito K; Caramori G; Adcock IM
    J Pharmacol Exp Ther; 2007 Apr; 321(1):1-8. PubMed ID: 17021257
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Phosphoinositide 3-kinase delta inhibitor as a novel therapeutic agent in asthma.
    Park SJ; Min KH; Lee YC
    Respirology; 2008 Nov; 13(6):764-71. PubMed ID: 18811876
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Inhibition of PI-3 kinase for treating respiratory disease: good idea or bad idea?
    Thomas M; Owen C
    Curr Opin Pharmacol; 2008 Jun; 8(3):267-74. PubMed ID: 18394961
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Phosphoinositide 3-kinases and their role in inflammation: potential clinical targets in atherosclerosis?
    Fougerat A; Gayral S; Malet N; Briand-Mesange F; Breton-Douillon M; Laffargue M
    Clin Sci (Lond); 2009 May; 116(11):791-804. PubMed ID: 19397491
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Phosphatidylinositol 3-kinase isoforms as targets in respiratory disease.
    Marwick JA; Chung KF; Adcock IM
    Ther Adv Respir Dis; 2010 Feb; 4(1):19-34. PubMed ID: 20051446
    [TBL] [Abstract][Full Text] [Related]  

  • 6. The pathophysiological roles of PI3Ks and therapeutic potential of selective inhibitors in allergic inflammation.
    Takeda M; Ito W; Tanabe M; Ueki S; Kihara J; Kato H; Tanigai T; Kayaba H; Sasaki T; Chihara J
    Int Arch Allergy Immunol; 2010; 152 Suppl 1():90-5. PubMed ID: 20523070
    [TBL] [Abstract][Full Text] [Related]  

  • 7. PI3K delta and PI3K gamma: partners in crime in inflammation in rheumatoid arthritis and beyond?
    Rommel C; Camps M; Ji H
    Nat Rev Immunol; 2007 Mar; 7(3):191-201. PubMed ID: 17290298
    [TBL] [Abstract][Full Text] [Related]  

  • 8. The biological effects of isoform-specific PI3-kinase inhibition.
    Ihle NT; Powis G
    Curr Opin Drug Discov Devel; 2010 Jan; 13(1):41-9. PubMed ID: 20047145
    [TBL] [Abstract][Full Text] [Related]  

  • 9. PI3K isoforms as drug targets in inflammatory diseases: lessons from pharmacological and genetic strategies.
    Harris SJ; Foster JG; Ward SG
    Curr Opin Investig Drugs; 2009 Nov; 10(11):1151-62. PubMed ID: 19876783
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Kinase inhibitors and airway inflammation.
    Adcock IM; Chung KF; Caramori G; Ito K
    Eur J Pharmacol; 2006 Mar; 533(1-3):118-32. PubMed ID: 16469308
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Aerosolized phosphoinositide 3-kinase gamma/delta inhibitor TG100-115 [3-[2,4-diamino-6-(3-hydroxyphenyl)pteridin-7-yl]phenol] as a therapeutic candidate for asthma and chronic obstructive pulmonary disease.
    Doukas J; Eide L; Stebbins K; Racanelli-Layton A; Dellamary L; Martin M; Dneprovskaia E; Noronha G; Soll R; Wrasidlo W; Acevedo LM; Cheresh DA
    J Pharmacol Exp Ther; 2009 Mar; 328(3):758-65. PubMed ID: 19056934
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Phosphatidylinositol-3-kinase/Akt signaling pathway and kidney cancer, and the therapeutic potential of phosphatidylinositol-3-kinase/Akt inhibitors.
    Porta C; Figlin RA
    J Urol; 2009 Dec; 182(6):2569-77. PubMed ID: 19836781
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Novel signal transduction modulators for the treatment of airway diseases.
    Barnes PJ
    Pharmacol Ther; 2006 Jan; 109(1-2):238-45. PubMed ID: 16171872
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Targeting remodeling in respiratory inflammation.
    Knox AJ; Pang L; Zhu YM
    Curr Opin Investig Drugs; 2000 Dec; 1(4):428-34. PubMed ID: 11249695
    [TBL] [Abstract][Full Text] [Related]  

  • 15. The phosphatidylinositol 3-kinase/Akt pathway negatively regulates Nod2-mediated NF-kappaB pathway.
    Zhao L; Lee JY; Hwang DH
    Biochem Pharmacol; 2008 Apr; 75(7):1515-25. PubMed ID: 18243161
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Targeting the PI3K-AKT-mTOR pathway: progress, pitfalls, and promises.
    Yap TA; Garrett MD; Walton MI; Raynaud F; de Bono JS; Workman P
    Curr Opin Pharmacol; 2008 Aug; 8(4):393-412. PubMed ID: 18721898
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Taming the PI3K team to hold inflammation and cancer at bay.
    Hirsch E; Ciraolo E; Ghigo A; Costa C
    Pharmacol Ther; 2008 May; 118(2):192-205. PubMed ID: 18420279
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Targeting the PI3K p110alpha isoform inhibits medulloblastoma proliferation, chemoresistance, and migration.
    Guerreiro AS; Fattet S; Fischer B; Shalaby T; Jackson SP; Schoenwaelder SM; Grotzer MA; Delattre O; Arcaro A
    Clin Cancer Res; 2008 Nov; 14(21):6761-9. PubMed ID: 18980969
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Parallel signaling pathways in endothelin-1-induced proliferation of U373MG astrocytoma cells.
    He S; Dibas A; Yorio T; Prasanna G
    Exp Biol Med (Maywood); 2007 Mar; 232(3):370-84. PubMed ID: 17327470
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Hepatocyte growth factor prevents advanced glycation end products-induced injury and oxidative stress through a PI3K/Akt-dependent pathway in human endothelial cells.
    Zhou YJ; Yang HW; Wang XG; Zhang H
    Life Sci; 2009 Nov; 85(19-20):670-7. PubMed ID: 19778541
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.